Drug | Approximate Difference in Mean/Median Concentrations (AUC) Compared with *1 / *1, Unless Otherwise Stated | Evidence for Genotyping | Evidence against Genotyping | References for Pharmacokinetic Data |
---|---|---|---|---|
Celecoxib | Single dose: *1 / *3: 1.4- to 2.2-fold; *3 / *3: 2.2- to 9-fold; *1 / *2, *2 / *2, and *2 / *3: not different; repeated dosing: *3 / *3: 1.0- to 8-fold; *1 / *2, *2 / *2, and *1 / *3: not different | Little evidence for altered effect; relatively high therapeutic index | Tang et al. (2001); Brenner et al. (2003); Kirchheiner et al. (2003e); Stempak et al. (2005); Lundblad et al. (2006) | |
Fluvastatin | Repeated dosing: 3R,5S-enantiomer (active): *1 / *3: 1.3-fold; *2 / *3: 2.2-fold; *3 / *3: 3.1-fold; *1 / *2 and *2 / *2: not different | Clinical implications unclear; high therapeutic index | Kirchheiner et al. (2003b) | |
Glimepiride | Single dose: *1 / *3 or *2 / *3: 1.3- to 2.7-fold; *3 / *3: 1.5-fold; *1 / *2: not different | Suggestion of increased hypoglycemia in PM | Implications of active metabolite not known | Niemi et al. (2002); Wang et al. (2005) |
Glyburide | Single dose: *1 / *3 or *2 / *3: 1.4- to 2.8-fold (N.S. in some studies); *3 / *3: 2.3-fold; *1 / *2 and *2 / *2: not different | Suggestion of increased hypoglycemia in PM | Kirchheiner et al. (2002b); Niemi et al. (2002); Yin et al. (2005) | |
Ibuprofen | Single dose: *1 / *3: 1.6- to 1.8-fold *2 / *3: 1.4- to 3.0-fold (N.S. in all studies); *3 / *3: 1.8- to 2.7-fold; *1 / *2 and *2 / *2: not different | Clinical implications unclear; relatively high therapeutic index; enantiomers complicate interpretation | Kirchheiner et al. (2002c); Garcia-Martin et al. (2004) | |
Lornoxicam | Single dose: *1 / *2 or *1 / *3: 1.6- to 1.9-fold; *3 / *13: 39-fold | Clinical implications unclear; relatively high therapeutic index | Zhang et al. (2005b); Liu et al. (2006) | |
Losartan | Single dose: no significant difference for losartan or E-3174, although latter metabolite was 0.1 fold in *3 / *3 (n = 1) versus *1 / *1; repeated dosing: *1 / *2: 3-fold for losartan | Decreased production of the main active moiety, E-3174, with *3 / *3 genotype suggests lack of effect likely | Fischer et al. (2002); Yasar et al. (2002); Lee et al. (2003b); Sekino et al. (2003) | |
Phenytoin | Single dose: *1 / *2: 1.5-fold; *2 / *2: 2.7-fold (N.S.); *1 / *3: 1.5-fold; *2 / *3: 2.7-fold (N.S.) | Low therapeutic index; cases of homozygotes for low activity alleles (e.g., *3 / *3) suggest greater effect | Clinical value of genotyping remains to be determined in the context of an extensive history of use with therapeutic drug monitoring | Caraco et al. (2001) |
Piroxicam | Single dose: *1 / *2: 1.7-fold; *1 / *3: 1.7-fold | Clinical implications unclear; relatively high therapeutic index | Perini et al. (2005) | |
Tenoxicam | Single dose: *1 / *2: 1.4-fold; *1 / *3: 1.8-fold | Clinical implications unclear; relatively high therapeutic index | Vianna-Jorge et al. (2004) | |
Tolbutamide | Single dose: *1 / *2: 1.1- to 1.5-fold (N.S. in some studies); *1 / *3: 1.7- to 1.9-fold; *2 / *3: 2.2-fold; *3 / *3: 4.7- to 6.5-fold; *2 / *2: not different | Potentiated hypoglycemic effect in healthy volunteer study | Kirchheiner et al. (2002a); Lee at al. (2002b); Shon et al. (2002); Chen et al. (2005) | |
Torsemide | Single dose: *1 / *3: 1.5-fold; *2 / *3: 1.7-fold; *3 / *3: 2.8-fold; *1 / *2 and *2 / *2: not different | Data on clinical implications in patients lacking | Vormfelde et al. (2004) |
N.S., not significant